The Drugs of Tomorrow are in Humans Today

For many commercially relevant diseases, a discovery platform predicated on the mining of human proteins offers significant advantages. SimPep™ , the company's proprietary protein-protein interaction platform, optimizes clinical predictability by discovering and emulating active protein-protein interaction sites involved with the regulation of diseases with unmet needs.

SimPep™ incorporates a unique and proprietary set of algorithms developed by the scientific founders of Serometrix. This discovery platform allows the convergence of vast amounts of data from public domain genome and proteome resources. Unlike classical molecular modeling approaches, SimPep™ utilizes proprietary design rules taken from evolutionary biology queues. These design rules allow for the rapid identification of an array of potential regulatory targets and ligands, all with a high probability of biological relevance within a specific parallel regulatory network. These hits are then further refined, confirmed in vitro, and optimized using standardized structure based tools.

This approach enables Serometrix to deliver new and novel compounds for disease management, providing our development partners dramatically improved starting points for the clinical development of promising new classes of therapeutics.